Once-daily AZILECT^® is well tolerated.

• Once-daily AZILECT^® is an irreversible MAO-B inhibitor that prevents dopamine breakdown in the brain ¹
• First and only MAO-B inhibitor indicated as both initial monotherapy and adjunct therapy ¹
• First once-daily PD therapy ²
• Novel chemical structure without amphetamine metabolites ^1,3,4
• Five times more potent in inhibiting MAO-B in preclinical studies ^5†
• Metabolized by CYP1A2 rather than CYP2B6 and CYP2C19 liver isoenzymes ^1,6
• AZILECT^® has been studied in 1563 patients in 3 large multicenter trials, including 2 trials conducted by the Parkinson Study Group ^1,7,8,9

* Recommended initial dose as adjunct therapy is 0.5 mg administered once daily. If a sufficient clinical response is not achieved, the dose may be increased to 1 mg administered once daily.

^† The clinical relevance is unknown. AZILECT® inhibits MAO type B, but adequate studies to establish whether rasagiline is selective for MAO type B (MAO-B) in humans have not yet been conducted.

Please see important safety information and  complete prescribing information.

REFERENCES
1. AZILECT^® Prescribing Information.
2. Waters CH. Diagnosis and Management of Parkinson’s Disease. 3rd ed.West Islip, NY: Professional Communications, Inc.; 2002.
3. Lamensdorf I, Youdim MBH, Finberg JPM. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem. 1996;67(4):1532-1539.
4. Finberg JPM, Youdim MBH. Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology. 2002;43(7):1110-1118.
5. Finberg JPM, Lamensdorf I, Commissiong JW, Youdim MBH. Pharmacology and neuroprotective properties of rasagiline. J Neural Transm Suppl. 1996;48:95-101.
6. Hidestrand M, Oscarson M, Salonen JS, et al. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson‘s disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos. 2001;29(11):1480-1484.
7. The Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease. The TEMPO study. Arch Neurol. 2002;59(12):1937-1943.
8. The Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO study. Arch Neurol. 2005;62:241-248.
9. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365(9463):947-954.